Teleost fish express at least three estrogen receptor (ER) subtypes. To date, however, the individual role of these ER subtypes in regulating expression of estrogen responsive genes remains ambiguous. Here, we investigate putative roles of three ER subtypes in Japanese medaka (Oryzias latipes), using vitellogenin (VTG) I and II as model genes. We identify specific ligand/receptor/ promoter dynamics, using transient transactivation assays that incorporate luciferase reporters comprising 3kb promoter/enhancer regions of medaka VTGI and VTGII genes. Four steroidal estrogens (17β-estradiol, estrone, estriol, and 17α-estradiol) were tested in these assays. Results indicate that all three medaka ERs (mERs) are capable of initiating transactivation of both VTG I and II, with mERβ2 exhibiting the greatest efficacy. Promoter deletion analysis suggests that ligand-specific receptor transactivation and utilization of regional-specific estrogen response elements may be associated with differential activities of each medaka ER. Further, cluster analysis of in vivo gene expression and transactivation suggests that all three ER subtypes putatively play a role in up-regulation of VTG. Results illustrate that preferential ligand/receptor/ promoter interactions may have direct implications for VTG gene expression and other ERmediated regulatory functions that are relevant to the risk assessment of estrogenic compounds.
INTRODUCTION
Endocrine active compounds (EACs) are exogenous compounds that alter function of the endocrine system, with the potential to cause adverse effects on individuals, their progeny, or their subsequent progeny. 1 Many EACs have been detected in surface waters throughout the United States, and have become of increasing concern over the past few decades due to impacts on fish populations. [2] [3] [4] [5] [6] Estrogenic EACs, a subclass of EACs, comprise a multitude of chemical classes including: natural estrogens (e.g., 17β-estradiol [E2β] and isoflavone), synthetic estrogens (e.g., 17α-ethynylestradiol and diethylstilbestrol) and estrogen mimics (e.g., nonylphenol and bisphenol A). 7 Surface waters contaminated with estrogenic EACs have been linked to a number of adverse effects in fish, including the aberrant expression of vitellogenin (VTG), a female specific egg yolk protein, in male fish. [8] [9] [10] [11] Continuous exposure to estrogenic contaminants may result in feminization and/or demasculinization within teleost populations, which may be linked to decreased reproductive output, compromised immunity, altered sex ratios, and ultimately population collapse. [12] [13] [14] [15] [16] [17] Given the potential risk to population, community and ecosystem sustainability, it is critical to gain a better understanding of the molecular initiating events (MIE) leading to adverse effects following exposure to estrogenic EACs.
Estrogenic EACs predominately mediate molecular, biochemical and ultimately physiological activities through the modulation of estrogen receptor (ER) signaling. ERs belong to a superfamily of nuclear receptors that regulate multiple cellular and physiological functions, ranging from bone growth to reproductive maturation. 18 Nuclear receptors are ligand-dependent transcription factors, which facilitate cellular responses to endogenous and exogenous ligands by coordinating complex transcriptional responses. 19 Classically, ligand activated ERs homodimerize, translocate into the nucleus, bind to estrogen response elements (EREs) and facilitate recruitment of co-regulators that govern gene transcription. Non-classically, ERs may heterodimerize with other transcription factors, interact with other DNA response elements, undergo ligand independent transactivation or mediate nongenomic signaling via membrane bound ERs. 18, [20] [21] [22] The focus of this study is the classical pathway of gene regulation.
In humans, there are two functional ER subtypes (α and β) that have distinct tissue distribution and physiological roles. 18, 23 In spite of ERβ arising from a genome duplication of ERα, ligand selectivity and specificity have diverged between the two receptors. 21, [24] [25] [26] [27] Studies also illustrate that target specificity of mammalian ERα and ERβ can be further enhanced through preferential interactions with specific EREs. 21, 26 In comparison to humans, teleost fish express at least three ERs (α, β1, and β2), with the second ERβ paralog arising from a subsequent fish-specific genome duplication event. [28] [29] [30] [31] [32] Similar to mammalian ERs, ligand binding assays indicate that teleost ER subtypes exhibit differential ligand selectivity and specificities, suggesting that receptor subfunctionalization has occurred. [33] [34] [35] [36] Additionally, teleost ER subtypes exhibit distinct tissue (e.g. liver, gonads, brain, muscles, kidney) distribution patterns 28, 30, [37] [38] [39] [40] [41] and dissimilar tissue specific induction/repression patterns following estrogen exposure. 37, 38, [42] [43] [44] Although a breadth of knowledge has accumulated since the discovery of a third ER in teleost fish, the respective function of all ER subtypes in transactivation of estrogen responsive genes remains equivocal.
VTG is perhaps the most widely used biomarker of estrogen exposure in oviparous species. [45] [46] [47] [48] [49] [50] [51] Studies in numerous fish species have shown that VTG induction is accompanied by a sharp increase in hepatic ERα expression, with little change in hepatic ERβ expression, 40, 43 implying that ERα may be the principle receptor mediating VTG gene induction. Studies in zebrafish (Danio rerio) and goldfish (Carassius auratus) suggest that ERβ subtypes may play a supporting role in VTG induction by inducing the up-regulation of ERα. 52, 53 Other studies have postulated that ERα is essential for initiating induction of VTG and other estrogen responsive genes (e.g. the egg envelope protein choriogenin [CHG]), while ERβ subtypes are necessary for sustaining and enhancing gene expression. 54, 55 These emerging models suggest that ERβ subtypes may be critical to vitellogenesis in the normal reproductive cycle of females, as well as to VTG/CHG induction in male fish that are exposed to estrogenic EACs. Yet, to date, few studies have demonstrated a direct role of ERβ subtypes in regulating VTG transcriptional activation.
This study seeks to elucidate the roles of the three ER subtypes in driving the transactivation of estrogen responsive genes, using Japanese medaka (Oryzias latipes) as a model organism, and VTG as a model gene. Medaka and other teleost fish have two VTG transcripts (VTGI and VTGII), resulting from a genome duplication event. 56 The roles of medaka (m) ERα, mERβ1 and mERβ2 in driving VTG expression were investigated in a series of transient transactivation assays using putative promoter/enhancer regions of the VTGI or VTGII gene. A VTG promoter/enhancer deletion analysis was also conducted to assess regulatory roles of putative EREs found within VTGI and VTGII promoters. Finally, in order to better examine the putative in vivo roles of ER subtypes following estrogen exposure, cluster analysis was used to assess correlations between VTG expression and co-activity/co-expression of ER subtypes. In vivo data used in this analysis was derived from a previous publication from our group. 44 For all assays, test compounds included four steroidal estrogens that are commonly detected in wastewater effluents: 17β-estradiol (E2β), estrone (E1), estriol (E3), and 17αestradiol (E2α).
further subcloned as full-length open reading frame from the ATG start to the TAG stop sequence in the pSG5 vector (details are provided in Table SI-1) . Three kb of the VTGII promoter (pVTGII) from −3005 to +1 of the VTGII translational start site was received as a generous gift from the Dr. Zhiyuan Gong (National University of Singapore, Singapore) in pEGFP 57 . Note this promoter/enhancer was originally described as VTGI regulator, but a refined analysis by our laboratory indicates its position upstream of VTGII within the current medaka genome. Assessment of an established transgenic line with the 3Kb VTGII-eGFP construct in medaka demonstrates concurrent expression of GFP and VTG in vivo, illustrating the regional regulation of VTG expression. 57 The VTGII promoter fragment was further subcloned into pGL4.10 vector using XhoI and HindIII restriction enzymes. To isolate the medaka VTGI promoter (pVTGI), Advantage® 2 polymerase chain reaction (PCR) long distance protocol (Clontech Laboratories Inc, Mountain View, CA) was used to isolate a 3.2 kb fragment −3243 to +1 of the VTGI translational start site from a medaka bacterial artificial chromosome clone (ola-068M06, NIBB/NBRP Medaka, Japan). Primers for pVTGI cloning were designed using Primer3 58, 59 with overhanging restriction enzyme sites (Supporting Information, Table SI-2). Amplicons from PCR reactions were cloned into pCR™2.1-TOPO vector using TOPO® Cloning Reaction Protocol (Life Technologies, Grand Island, NY). Promoter fragments were subsequently subcloned using restriction enzymes (KpnI, XhoI) into the pGL4.10 Photinus pyralis (firefly) luciferase reporter vector (Promega, Madison, WI).
Transient Transfection
HeLa cells (human cervical adenocarcinoma cells) were used due to the absence of endogenous ERs. 60 Cells were maintained in phenol red-free Dulbecco's Modified Eagle Medium (DMEM; Corning Inc, Corning, NY) fortified with 10% vol/vol fetal bovine serum (FBS; Corning Inc), 2.0mM L-glutamine (Corning Inc), and 1% antibiotic/antimycotic (Sigma-Aldrich, St. Louis, MO). During the assay, cells were maintained in hormone-free media containing 10% dextron/charcoal striped FBS (DCC-FBS; Corning Inc). Cells were seeded at a density of 10 5 cells per well in 96-well plates (Corning Inc) and allowed to attach overnight in 37°C incubator with 5% CO 2 and humidity. Cells were then transfected with 50 ng of pGL4-luc reporter construct (pVTGs-firefly) and 100 ng of pSG5-ER (mERα, mERβ1 or mERβ2) using Lipofectime 2000 (Life Technologies, Grand Island, NY). To control for variations in transfection efficiency, 20 ng of pRL-tk-luc (Promega), a Renilla reniformis (renilla) luciferase gene with constitutively active herpes simplex virus thymidine kinase promoter was co-transfected. Twenty-four hours post-transfection, cells were dosed with compounds of interest or solvent control (EtOH), the amount EtOH per well did not exceed 0.1% EtOH. Following a 24-hour dosing period, luciferase activity was determined using a Dual-Glo Luciferase Assay System (Promega) and FLOUstar Omega Filter-based multi-mode microplate reader (BMG Labtech, Ortenberg, Germany). Luciferase readings were initially normalized to Renilla luciferase to obtain firefly:renilla ratio. This ratio was further normalized to EtOH response (dividing by ETOH firefly:renilla ratio) to obtain transactivation.
Transactivation of mERs
The capacity of steroidal estrogens to transactivate mERs was assessed by transient transfection assay described above. Assays were conducted with E2β, E1, E3 or E2α concentrations ranging between 0.0001 and 10,000 nM. Sigmoid concentration-response curves were generated for each compound with all receptor/reporter pairs. Transactivation was plotted against log transformed concentration and fitted to the following symmetric logistic function, (Eq.) 1 with y as transactivation, × as concentration and bottom values constrained to 1, using Prism 5.0 software (GraphPad, La Jolla, CA; note: top values were not constrained because of difference in ligand/receptor efficacies). Steroidal estrogen responses were expressed as concentration that evoked half the maximum response (EC 50 ). The maximum efficacy (E MAX ; i.e., top) of each compound is additionally reported for each compound/receptor/ reporter combination. Each compound-dose was run as three technical replicates/plate, and each experiment was repeated 3-4 times.
Relative Potency of Steroidal Estrogens and Receptors
To compare potency between compounds with different E MAX values, data was further normalized to top and bottom of the E2β concentration-response curve for each receptor by calculating percent induction as described for yeast estrogen screen in a previous study, 44 Eq. 2 with y as transactivation. Percent induction was plotted against log transformed concentration, which was fitted to Eq. 1, with bottom constrained to 0. Percent induction of E1 and E2α did not exceed 50%. To account for the range in E MAX among the compounds, the concentration that produced 20% response (EC 20 ) was used to calculate the potency relative to E2β (relative estrogenic potency, or REP),
Eq. 3
To compare potency of the four steroidal estrogens across the three ER subtypes, EC 20 was used to calculate the potency at each receptor relative to mERα (mERα to mERx ratio), Eq. 4
VTG Promoter Deletion Analysis
Estrogen response elements (EREs) within both medaka VTGI and VTGII promoter/ enhancer regions were identified using NUBIscan V2.0 (University of Basel, Basel, Switzerland). The location of eight inverted repeat 3 (IR3) response elements were identified within the cloned 3.2 kb fragment of the pVTGI promoter and eleven IR3 response elements were identified within the cloned 3.0 kb fragment of the pVTGII promoter (Table SI-3) . Putative EREs were used to establish deletion constructs comprising 100%, 50% and 25% of the ~3kb proximal regulatory sequence of each pVTG via PCR, using Advantage® 2 PCR kit protocol and primers designed in Primer3 (Table SI- 2) . Amplified regions of each promoter were cloned into pCR™2.1-TOPO vector (as described above) and subsequently subcloned into pGL4.10. The VTGI 100%, 50% and 25% promoters contained eight, six and four putative EREs, respectively. The VTGII 100%, 50% and 25% promoter contained eleven, seven and three putative EREs, respectively ( Figure SI-1 ). Transactivational capacities of mERs with promoter fragments were assessed by transient transfection assay described above. Transactivational analysis was conducted with 1,000 nM of each steroidal estrogen to ensure maximal induction, and data was analyzed as fold transactivation. Each compound was run in triplicate/plate, and mean fold transactivation was calculated based on 2-3 assay replicates.
Assessment of Co-expression and Co-activation of mER subtypes with VTG
In a previous study, 44 our group conducted an analysis of in vivo hepatic gene expression in male medaka, in which the fish were exposed to four different steroidal estrogen treatments: 0.64 nM E2β, 1.42 nM E1, 89.20 nM E3, and 21.59 nM E2α, as well as a 0.01% EtOH control. The expression of several estrogen-responsive genes was evaluated using quantitative polymerase chain reaction (qPCR), including VTGI and VTGII. See Supporting Information for more details. To better assess in vitro co-activation of ER subtypes and in vivo co-expression of VTG, transactivation assays were repeated using the same ligand concentrations that were used in the in vivo exposures. This was done under the assumption that estrogen concentrations at the cellular level in fish were directly related to the exposure concentrations in water. Although this assumption does not take potential ADME (absorption, distribution, metabolism, and excretion) effects into account, we can only assume that the effects observed in fish were related to the exposure concentration.
Transactivation assays were conducted with each mER (mERα, mERβ1, mERβ2) and ~3kb VTGI or VTGII reporter constructs. Each compound was run in triplicate/plate and mean transactivation was calculated based on 2-3 assay replicates. Mean fold transactivations were then used in a bioinformatics summary described below.
Statistical Analysis
Graphs were developed and statistical analysis was conducted in Prism 5.0. Sharpiro-Wilk test and Barlette's test were used to test data for normality and equal variances, respectively. Transactivation from promoter deletion analysis and in vitro/in vivo comparison failed the normality test, so Wilcoxon pairwise analysis was conducted to determine effects of treatment and promoter region on transactivation. Two-way hierarchical clustering (Ward's method) of in vitro transactivation and in vivo gene expression from medaka exposure was conducted using JMP Pro 12 statistical software (SAS, Cary, NC). Cluster analysis included five treatments (0.01% EtOH, 0.64 nM E2β, 1.42 nM E1, 89.20 nM E3 and 21.59 nM E2α), in vitro transactivation of three ERs (mERα, mERβ1, and mERβ2) and in vivo expression of five genes (mERα, mERβ1, mERβ2, mVTGI and mVTGI).
RESULTS

Transactivation of mERs
Analysis of mER subtype activity with EtOH revealed that background transactivation was not significantly different (F-test, p>0.05) among three mER subtypes for both VTGI and VTGII ( Figure SI-2 ). Assessment of ER transactivation revealed that each steroidal estrogen (E2α, E2β, E1 and E3) transactivated all three receptor subtypes (mERα, mERβ1, mERβ2) with both pVTGI and pVTGII reporter constructs ( Figure 1 ). Consistently, E2β exhibited the highest potency of the four steroidal estrogens regardless of receptor subtype (Table 1) . E1 was generally the least potent compound. There was a noted exception: E1 and E2α exhibited similar potency in mERβ2 transactivation with both VTG reporters. Similarly, E3 and E2α exhibited similar potency in transactivation of mERα and mERβ1 with both VTG reporters. (Figure 1 and Table 1 ) revealed that regardless of ligand or pVTG reporter, the transactivational activity of mERβ2 was consistently greater than mERβ1 and mERα receptor subtypes. Similarly, E MAX of mERβ1 was larger than mERα, independent of ligand or reporter. Within each receptor, E MAX values suggests that steroidal estrogens functioned as either full or partial agonist. In comparison to the efficacy of E2β (considered a full agonist), E1, E3 and E2α were generally partial agonists. There were a few exceptions: E1 exhibited full agonist activity with mERβ1-pVTGI; E3 exhibited full agonist activity with mERα-pVTGI, mERα-pVTGII, and mERβ1-pVTGII; and E2α exhibited full agonist activity with mERα-pVTGI.
Analysis of E MAX
Relative Potency of Steroidal Estrogens and Receptors
To compare the potency among the four steroidal estrogens and three receptors with different E MAX values, data was normalized to E MAX of E2β within each receptor subtype ( Figure SI-3 ) and EC 20 values (Table 2) were used as described in experimental methods. Assessment of REPs revealed that E1, E3, and E2α were less potent than E2β across all three receptors and with both pVTGI and pVTGII reporters ( Table 2 ). Rank order of potency were: E2β>E2α≳E3>E1 for mERα; E2β>E3≳E2α>E1 for mERβ1; and E2β>E3>E2α≈E1 for mERβ2. Analysis of compound potency with each receptor relative to mERα (mERα:mERx) revealed that the potency of E2β and E3 was 3.0-17.3 times greater with the mERβs relative to mERα. In contrast, the potency of E1 and E2α was similar or lower with the mERβs relative to mERα, with one exception: with pVTG1, the potency of E2α was 6.7 times greater with mERβ1 relative to mERα.
VTG Promoter Deletion Analysis
Transfection studies with VTG promoter deletion constructs ( Figure SI-1) for pVTGI indicates that all three promoter constructs (100%, 50% and 25%) were active with each ER subtype and each ligand tested (Figure 2A -C) with one exception: E2α did not transactivate mERα-50%pVTGI. Two general patterns of transactivation emerged among the promoter/ enhancer regions of pVTGI. The most common pattern was 25%pVTGI < 50%pVTGI < 100%pVTGI, in which transactivation with 25%pVTGI was significantly lower than 100%pVTGI, but 25%pVTGI and 100%pVTGI were not significantly different from 50%pVTGI. The other pattern was 25%pVTGI ≈ 50%pVTGI, with both being significantly lower than 100%pVTGI. There were two exceptions to these patterns. For E2α-mERα, transactivation with 50%pVTGI was significantly lower than 100%pVTGI, and transactivation of both 50%pVTGI and 100%pVTGI were not significantly different from 25%pVTGI (Figure 2A) . For E1-mERβ1, transactivation with 25%pVTGI was significantly lower than both 50%pVTGI and 100%pVTGI ( Figure 2B ).
Transactivation data for pVTGII demonstrates that only 100% and 50% promoter constructs were active, with the following exceptions: E2β-mERα, E3-mERβ2 and E2α-mERβ2 were active with the 25%pVTGII (Figure 2D-F) . For most receptor/ligand combinations, a general pattern was observed in which transactivation with 50%pVTGII was lower than 100%pVTGII (although generally not significantly lower), and both were significantly greater than 25%pVTGII.
Assessment of Co-expression and Co-activation of mER subtypes with VTG
Our group has previously published an analysis of the in vivo response of male medaka to estrogenic ligands, including E2β, E1, E3, and E2α. 44 Gene expression results from this study are summarized in Table SI-5. To provide an assessment of co-expression and coactivation, a second set of transactivation assays were conducted using the same steroidal estrogen concentrations that were utilized in the in vivo medaka exposures. In these assays, fold transactivation was generally larger with E2β and E3 compared to E2α and E1, independent of receptor and pVTG reporter ( Table 3 ). In addition, among the three receptors, fold transactivation was consistently larger with ERβ2, followed by ERβ1.
Two-way hierarchical cluster analysis was conducted to establish putative relationships between gene expression following steroidal estrogen treatments (Table SI-5) and transactivation of mER subtypes (Table 3 ). For pVTG1, cluster analysis of steroidal estrogen treatment groups resulted in resulted in two empirical clusters of C1 [E2β and E3 treatments] and C2 [E1, E2α treatments and EtOH]. Within C2, E1 and E2α formed a subcluster independent of EtOH ( Figure 3A ). Hierarchical clustering of data generated using the VTGII reporter ( Figure 3B 
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DISCUSSION
To elucidate the differential roles of teleost ER subtypes in estrogen-induced gene induction, we investigated the transactivation capacity of three mER subtypes, using VTGI and VTGII as prototypic target genes. Through the use of novel luciferase reporter constructs incorporating 3 kb upstream regions of mVTGI and mVTGII genes, we illustrate distinct ligand potency and receptor efficacy patterns among three mER subtypes. To our knowledge, this is the first study to demonstrate interaction and functionality of all three ER subtypes with tangible promoter/enhancer regions of the VTGI and VTGII genes, which contain multiple EREs.
For VTGI and VTGII, our results show that mERβ2 exhibits greater efficacy than mERβ1 and mERα. This pattern was consistent across all four steroidal estrogens analyzed (E2β, E1, E3 and E2α), suggesting that mERβ2 may play a larger role in up-regulation of VTGs genes. This observation is similar to previous studies examining transactivational activity of medaka, tilapia and zebrafish ERs, which found that efficacy was greater with ERβ2 relative to ERβ1 and ERα. 38, 42, 61 However, other species of fish, such as largemouth bass and carp, exhibit an opposite pattern of receptor activity, with ERα having a greater efficacy compared to ERβs. 29, 30 This discrepancy implies that interspecies differences may exist with regards to ER subfunctionalization.
We also observed that ligand potencies remained relatively consistent across each of the three mERs and across both of the pVTG reporters, with E2β consistently found to be the most potent ligand. This was followed by E3 and E2α, which were frequently equipotent. The least potent estrogen was often E1. This is consistent with steroidal estrogen activities in carp, 30 where E1 was generally the least potent or equal in potency to E3. Conversely, E1 has been shown to be equipotent to E2β in roach, 62 further implying that ER subfunctionalization may not have co-evolved across teleost fish.
Although we observed general trends in potency among the four steroidal estrogens, our results also suggest that there are distinct activity groupings among the estrogens with respect to the different ER and promoter subtypes. In almost all cases, E2β and E3 exhibited greater potency with mERβ1 and mERβ2 than with mERα. This coincides with ligand affinity data in medaka and Atlantic croaker (Micropoganias undulates), 33, 44 which found that E2β and E3 had higher affinity for the ERβs compared to ERα. Furthermore, E1 and E2α had similar transactivation patterns, having equivalent or lower potencies with mERβ1 and mERβ2 relative to mERα. Ligand binding data also illustrate that both compounds have greater affinity for ERα than the ERβs. 33, 44 Possibly, the estrogens within these two pairs (E2β/E3 and E1/E2α) elicit similar structural and transactivational modifications (such as recruitment of co-regulators) to mERs that result in comparable functional activities. Tohyama et al. 63 illustrate that binding to specific residues within the binding pocket of mERs confers ligand-specific activity. Similarly, through promoter deletion analysis we revealed that ligand-receptor pairs utilize specific and distinct regions of DNA regulatory regions, and this varied between VTGI and VTGII. In humans, ER subtypes bind to specific and sometimes different chromatin binding regions, 26 and binding to specific EREs is proposed to effect co-regulator recruitment and receptor configurations, ultimately leading to enhanced/repressed transcriptional activity. 21 A similar mechanism may explain differential and specific transactivational activities among the mER subtypes. Further investigation of co-regulator recruitment and chromatin binding assays may shed more light on the divergences among the three ER subtypes.
Ultimately, we set out to investigate the respective roles of teleost ER subtypes following estrogen exposure. Our bioinformatics analysis indicated a strong association between transactivational activity of mERβ2 and in vivo VTG expression levels. In addition, in vivo VTG expression was clustered, although not as closely, with expression levels of mERα and transactivation activity of mERα and mERβ1. This corroborates previous studies illustrating that both ERα and ERβs are necessary for vitellogenesis in medaka, zebrafish and goldfish. [52] [53] [54] Yamaguchi and colleagues also illustrate that all three mER subtypes are capable of regulating mVTG and mCHG expression, in a study which used mERα-and mERβ-selective agonists (orthoester-2k and 2-(4-hydroxyphenyl)-5-hydroxy-1,3benzoxazole [HPHB], respectively). 54, 55 Several recent studies have proposed hypotheses on the respective roles of ERα and ERβ in the up-regulation of estrogenic biomarkers in teleost fish. Yamaguchi and colleagues propose that mERα plays a role in initiating the expression of mVTGII and mCHG-Heavy (H), while mERβs enhance and sustain expression of these genes. 54, 55 Using increasing concentrations of orthoester-2k and a constant concentration of HPHB, they illustrate that the mERβ significantly enhances the up-regulation of mCHG-H and mVTGII by mERα. They document the inverse results with mCHG-Light (L), suggesting mERα may enhance the up-regulation of mCHG-L by mERβ. 54, 55 Other studies have proposed that hepatic ERβs play a role in up-regulating the expression of ERα upon estrogen stimulation, and thus are important for priming hepatocytes for vitellogenin production. 52, 53 Our bioinformatics and transactivational assessments with mVTGI and mVTGII, suggest that indeed all three ERs are likely involved in this process.
In our previous study, 44 we demonstrated that in vivo exposure to steroidal estrogens results in a large significant increase in mERα gene expression, and a smaller but significant decrease in mERβs. This occurred simultaneously with an increase in mVTG and mCHG, similar to findings in several other fish species. 37, 43, [64] [65] [66] This is reflected by the correlation between expression levels of mERα and mVTGs, observed in the cluster analysis. The fact that mERα exhibits significant yet low transactivational activity with endogenous estrogenic steroids, is up-regulated simultaneously with mVTG, and clusters close to VTG expression, could support the hypothesis that mERα is associated with the initial induction of VTG. Furthermore, the high transactivation capacity of ERβs (especially ERβ2) and clustering of mERβ2 transactivation to mVTG expression, could support the notion that mERβs (possibly just mERβ2) maintain the ability to directly sustain and/or enhance expression of VTGs. Additional studies, perhaps using selective mERα-and mERβ-specific agonists, would be necessarily in order to fully delineate these roles. Regardless, this combined evidence suggests that VTG up-regulation is likely driven by interplay between these multiple ER subtypes.
The patterns of receptor-based ligand potency and efficacy observed here and in other recent studies also implies that classical methods of screening surface waters for estrogenic activity may not be adequate for the ecological assessment of fish health. Estrogenic activity of environmental media is often assessed using bioassays such as the yeast estrogen screen, T47D-KBluc, and E-Screen. Each of these assays report activation of human ERs, and often only utilize ERα. 46, [67] [68] [69] [70] Our observations suggest that mammalian ER based assays may not recapitulate estrogenic responses in teleost. For example, the four estrogens tested in this study generally function as full agonists in mammalian cell-based estrogen screening assays. 71, 72 In contrast, we demonstrate that E1, E3, and E2α generally functioned as partial agonists in the medaka model. With regards to the potencies of estrogenic ligands, most mammalian ER studies report a rank order of E2β>E1>E2α>E3. 35, 71, 72 In contrast, we found that E1 was generally the least potent of these steroidal estrogens across all three mERs. This supports a divergence between mammalian and teleost ERs as demonstrated by Davis et al. 42 These differences in ligand potency and efficacy, in conjunction with the lack of conservation with selective ER agonists and antagonists between mammalian and teleost models, suggest that ER responsiveness may have diverged over the course of teleostmammalian ER evolution.
Another factor that may impact the predictive capabilities of ER-based screening assays is that fish species may differ from one another with regards to ER activity. As discussed above, studies in other fish species have observed ligand potencies and ER efficacies that contrast with our observation in medaka. This is corroborated by observations by Lange et al., 73 who documented differences in sensitivities to five estrogens (E2β, E1, E3, 17αethynylestradiol and diethylstilbestrol) among six fish species (medaka, carp, zebrafish, fathead minnow [Pimephales promelas], roach and stickleback [Gasterosteus aculeatus]), using in vitro and in vivo models. Taken together, these variations suggest that interspecies differences may exist in the activity of teleost ERs, suggesting that assays using ERs from a single species may not be sufficient in assessing potential risk to fish populations and communities.
A third factor that may impact the predictive capabilities of ER-based screening assays is the use of synthetic EREs in these assays. As stated previously, our study employed transactivation assays that were regulated by endogenous VTG gene promoter sequences, while other recent studies have employed transactivation assays that are regulated by synthetic EREs. We observed that the efficacy of steroidal estrogens in our assays was considerably greater than that observed in other recent studies examining ER transactivation. 30, 38, 42, 61, 65 To further assess these differences, we performed a follow-up experiment in which we evaluated the transactivation of all three mERs using a synthetic ERE reporters in the presence of E2β (data in Supporting Information). Analysis revealed that for all three mER subtypes, efficacy was larger with both pVTG reporters relative to synthetic ERE ( Figure SI-4 ). This provides suggestive evidence that reporter assays driven by synthetic EREs may be underestimating functional activity. This is yet another factor that may impact in vitro to in vivo extrapolation for estrogenic EACs, and another limitation of the in vitro assays that are classically used to evaluate estrogenic activity.
In sum, we employed novel transactivation assays and provide evidence that all three mERs have the capacity to regulate mVTG expression. Efficacy and potency patterns suggest subfunctionalization occurred among the mER subtypes, which may be critical in initiation and enhancement of estrogen responsive genes. Through this novel approach, we were able to enhance the current understanding of MIEs following estrogen exposure in medaka. Simultaneously, we shed light on several potential concerns over using classical screening assays to evaluate estrogenic activity in surface water: discrepancies between mammalian and piscine ER subtypes, interspecies differences within fish populations, and potential inefficiencies with synthetic EREs. These variables should be kept in mind when considering the hazards posed to fish populations by estrogenic EACs. Given possible interspecies discrepancies in ER subtypes (among teleost fish and between mammals) and growing knowledge on the ERβs activity, there is a necessity to re-examine current toxicity testing methods used in ecological assessments. Hierarchical clustering analysis of genes analyzed and fold transactivation (T) for VTGI (A) and VTGII (B) from medaka exposure. Relative up-regulation of genes (in vivo) and high transactivation are expressed from high (grey) to low (black) relative to each parameter. A two-way cluster was conducted with the five treatments: 17β-estradiol (E2β), estrone (E1), estriol (E3) and 17α-estradiol (E2α) and activity: gene expression and transactivation using Ward's method. C# and SC# denote clusters numbers and sub-cluster numbers. Table 2 Relative estrogenic potency (REP) and mERα:mERx ratio for steroidal estrogens at each mER subtype and VTG promoter construct. Table 3 Mean (±standard error, italicized) fold transactivation of medaka estrogen receptors, at the exposure concentrations used for comparison with in vivo data. * 
